Fundamental Analysis of CRONOS GROUP INC(NASDAQ:CRON) stock

Fundamental Rating

CRON gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. CRON has a great financial health rating, but its profitability evaluates not so good. CRON is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CRON has reported negative net income.

CRON had a negative operating cash flow in the past year.

CRON had negative earnings in 4 of the past 5 years.

CRON had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -6.49%, CRON is doing good in the industry, outperforming 76.92% of the companies in the same industry.

CRON has a Return On Equity of -6.73%. This is amongst the best in the industry. CRON outperforms 80.51% of its industry peers.

		Industry Rank	Sector Rank
ROA	-6.49%
ROE	-6.73%
ROIC	N/A

ROA(3y)-16.25%

ROA(5y)0.65%

ROE(3y)-17.03%

ROE(5y)2.26%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of CRON (12.93%) is comparable to the rest of the industry.

In the last couple of years the Gross Margin of CRON has declined.

The Profit Margin and Operating Margin are not available for CRON so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	12.93%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y-23.24%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for CRON remains at a similar level compared to 1 year ago.

The number of shares outstanding for CRON has been increased compared to 5 years ago.

There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 14.62 indicates that CRON is not in any danger for bankruptcy at the moment.

CRON has a better Altman-Z score (14.62) than 91.79% of its industry peers.

CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	14.62

ROIC/WACCN/A

WACC8.08%

2.3 Liquidity

CRON has a Current Ratio of 22.54. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.

CRON has a better Current ratio (22.54) than 96.92% of its industry peers.

A Quick Ratio of 21.81 indicates that CRON has no problem at all paying its short term obligations.

CRON has a better Quick ratio (21.81) than 96.41% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	22.54
Quick Ratio	21.81

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 75.56% over the past year.

Looking at the last year, CRON shows a decrease in Revenue. The Revenue has decreased by -4.37% in the last year.

The Revenue has been growing by 48.40% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)75.56%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q76.19%

Revenue 1Y (TTM)-4.37%

Revenue growth 3Y23.14%

Revenue growth 5Y48.4%

Revenue growth Q2Q4.49%

3.2 Future

Based on estimates for the next years, CRON will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.23% on average per year.

CRON is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.41% yearly.

EPS Next Y14.23%

EPS Next 2Y-9.79%

EPS Next 3Y5.24%

EPS Next 5Y10.23%

Revenue Next Year14.53%

Revenue Next 2Y16.49%

Revenue Next 3Y15.78%

Revenue Next 5Y12.41%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CRON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year CRON is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-9.79%

EPS Next 3Y5.24%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CRON does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CRONOS GROUP INC

NASDAQ:CRON (4/23/2024, 10:18:00 AM)

2.465

+0.1 (+4.45%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap939.90M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-6.49%
ROE	-6.73%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	12.93%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.08

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	22.54
Quick Ratio	21.81
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)75.56%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y14.23%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-4.37%

Revenue growth 3Y23.14%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CRONOS GROUP INC (CRON)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens